Posts by tag

Pharma Industry

373 posts
View Post
  • 6 min

WHO Prequalifies First Ever Malaria Treatment for Newborns and Infants – Asrar Qureshi’s Blog Post #1259

The WHO’s approval of Coartem Baby marks a historic achievement in malaria treatment for newborns and young infants, addressing a critical gap in healthcare. Developed by Novartis and Medicines for Malaria Venture, this innovative drug provides a safer, accurately dosed option, highlighting the importance of inclusive pharmaceutical innovation and collaborative efforts in global health.
Share
View Post
  • 5 min

Cost of Incentives to Work Life Balance – Asrar Qureshi’s Blog Post #1258

Asrar Qureshi’s Blog Post 1257 discusses the impact of performance incentives in the pharmaceutical industry. While rewards drive productivity, they can also lead to work-life imbalance, burnout, and a narrow definition of success, emphasizing metrics over well-being. The post advocates for redesigning incentives to promote sustainable practices and prioritize employee wellness.
Share
View Post
  • 6 min

Doctors & Pharma Industry – Part 2 of 2 – Asrar Qureshi’s Blog Post #1218

Asrar Qureshi’s Blog Post #1218 addresses the complex relationship between pharmaceutical companies and doctors, emphasizing the need for ethical conduct in Pakistan’s healthcare system. It outlines a Code of Conduct for both sectors, aiming to balance industry collaboration with patient welfare, maintaining professionalism while avoiding conflicts of interest.
Share
View Post
  • 5 min

Doctors & Pharma Industry – Part 1 of 2 – Asrar Qureshi’s Blog Post 1217

The blog post by Asrar Qureshi explores the complex relationship between pharmaceutical companies and doctors, emphasizing its dual nature of necessity and ethical risk. It advocates for transparency and independence in education, particularly in the context of Pakistan’s healthcare challenges. The post highlights both issues and contributions of this relationship in improving patient access to treatment.
Share
View Post
  • 6 min

Pharmaceutical Distribution Systems – A Strategic Opportunity – Asrar Qureshi’s Blog Post #1215

Asrar Qureshi’s blog post discusses the urgent need for modernizing pharmaceutical distribution in Pakistan, shifting from a traditional logistics model to a strategic healthcare framework. It emphasizes cold-chain capabilities and digital transformation to improve patient outcomes as the market evolves towards specialty medicines and biologics, urging collaboration among stakeholders.
Share
View Post
  • 5 min

Active Pharmaceutical Ingredients Manufacturing in Pakistan – Asrar Qureshi’s Blog Post #1207

Asrar Qureshi’s blog highlights Pakistan’s critical API import dependence and the necessity for local API manufacturing. With over 85% APIs imported, this reliance poses health and economic risks. Establishing domestic plants is essential for health security, export competitiveness, and economic resilience. Past missed opportunities emphasize the urgency for investment and strategic initiatives.
Share
View Post
  • 6 min

Kiran Mazumdar-Shaw’s Bold Healthcare Mission – Asrar Qureshi’s Blog Post #1203

Asrar Qureshi’s blog post highlights Kiran Mazumdar-Shaw’s transformative journey with Biocon, emphasizing her mission-driven leadership in biotechnology. She advocates for affordable, accessible healthcare and resilient innovation, turning challenges into opportunities. Mazumdar-Shaw’s insights stress the importance of purpose, collaboration, and ecosystem development in creating impactful healthcare solutions for emerging markets.
Share
View Post
  • 6 min

Antimicrobial Resistance – The Silent Crisis – Asrar Qureshi’s Blog Post #1192

Antimicrobial resistance (AMR) poses a critical global threat, causing over a million deaths annually. The WHO emphasizes the need for a “One Health” approach to combat AMR, integrating human, animal, and environmental health. The pharmaceutical industry must invest in research, support stewardship, and advocate for policy changes to safeguard antimicrobials and ensure health sustainability.
Share